Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials

References

• Amann VC, Ramelyte E, Thurneysen S, et al. Developments in targeted therapy in melanoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2017;43:581-93
   Google Scholar
• Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med 2014;3:229-35
   PubMedGoogle Scholar
• Abdel-Rahman O. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations. Ther Adv Respir Dis 2016;10:265-74
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Kohno M, Tanimura S, Ozaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull 2011;34:1781-4
   PubMed Web of Science ®Google Scholar
• Roskoski R, Jr. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharm Res 2017;117:20-31
   Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015;7:122-36
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9
   PubMed Web of Science ®Google Scholar
• Higgins J, Altman D, Gøtzsche P, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Br Med J 2011;343:d5928
   PubMed Web of Science ®Google Scholar
• Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011;29:1021-8
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Smit EF, Planchard D, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger. Ann Oncol Off J Eur Soc Med Oncol 2015;26:894-901
   PubMed Web of Science ®Google Scholar
• Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012;30:1216-23
   PubMed Web of Science ®Google Scholar
• Carvajal R, Sosman J, Quevedo J, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014;311:2397-405
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
   PubMed Web of Science ®Google Scholar
• Gupta A, Love S, Schuh A, et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. J Clin Oncol 2013;31:a9068
   Google Scholar
• Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014;50:2072-81
   PubMed Web of Science ®Google Scholar
• Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-88
   PubMed Web of Science ®Google Scholar
• Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013;14:733-40
   PubMed Web of Science ®Google Scholar
• Zaman K, Winterhalder R, Mamot C, et al. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015;51:1212-20
   PubMed Web of Science ®Google Scholar
• Signorelli J, Shah Gandhi A. Cobimetinib. Ann Pharmacother 2017;51:146-53
   PubMed Web of Science ®Google Scholar
• Rosen LS, LoRusso P, Ma WW, et al. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs 2016;34:604-13
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40
   PubMed Web of Science ®Google Scholar
• Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013;6:27
   PubMed Web of Science ®Google Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2008;14:342-6
   PubMed Web of Science ®Google Scholar
• McCubrey J, Steelman L, Chappell W, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012;3:1068-111
   PubMed Web of Science ®Google Scholar
• Wright CJ, McCormack PL. Trametinib: first global approval. Drugs 2013;73:1245-54
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010;5:1630-6
   PubMed Web of Science ®Google Scholar
• Cho S, Atwood JE. Peripheral edema. Am J Med 2002;113:580-6
   PubMed Web of Science ®Google Scholar
• Brodovicz KG, McNaughton K, Uemura N, et al. Reliability and feasibility of methods to quantitatively assess peripheral edema. Clin Med Res 2009;7:21-31
   PubMedGoogle Scholar
• Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol 2014;25:1437-41
   PubMed Web of Science ®Google Scholar
• Thota R, Johnson DB, Sosman JA. Trametinib in the treatment of melanoma. Expert Opin Biol Ther 2015;15:735-47
   PubMed Web of Science ®Google Scholar
• Hartmann J, Haap M, Kopp H, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Miller VA, Ng KK, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol 2003;26:247-51
   PubMed Web of Science ®Google Scholar
• Schirger A. DDx and management of leg edema in the elderly. Geriatrics 1982;37:26-32
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51
   PubMed Web of Science ®Google Scholar